Holen Sie sich die Stockscreener-App
2.31
6.45%
0.14
Handel nachbörslich:
2.31
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene schedules May 13 webcast for Q1 results and business update - Stock Titan
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - ChartMill
Allogene Therapeutics ALPHA3 trial explores allogeneic CAR T potential in LBCL treatment - Traders Union
MSN Money - MSN
Allogene Therapeutics spotlights CTO participation in cell therapy innovation forum - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock - Insider Monkey
[ARS] Allogene Therapeutics, Inc. SEC Filing - Stock Titan
Allogene (NASDAQ: ALLO) proxy backs share authorization boost and pay votes - Stock Titan
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene licensor Cellectis faces patent lawsuit in the U.S. - MSN
JP Morgan Upgrades Allogene Therapeutics (ALLO) - MSN
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN
Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance
10 Best Growth Stocks Under $10 to Invest In - Insider Monkey
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union
Allogene Therapeutics announces public offering of $175M of common stock - MSN
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat
[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey
Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India
Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates - Stocktwits
Allogene Therapeutics, Inc.Common Stock (NQ: ALLO - FinancialContent
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan
Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6%Should You Sell? - MarketBeat
Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus
Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia - marketscreener.com
Allogene expands lymphoma trial to South Korea, Australia - Investing.com
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):